What the studies show
Pooled incidence of low sodium 7.6% in older adults treated for nocturia — the reason for sodium checks before and during treatment and for the boxed warning on the US nasal product.
“The pooled estimate for the incidence of hyponatremia was 7.6% (95% CI 3.7-15.1).”
Several well-run randomised trials in people, pointing the same way. You can plan around this. It still says nothing about whether the effect is worth the side effects for you.
- 1Weatherall M. The risk of hyponatremia in older adults using desmopressin for nocturia: a systematic review and meta-analysis.Neurourol Urodyn, 2004Pooled incidence 7.6%.
In context
Desmopressin is a synthetic analogue of the antidiuretic hormone vasopressin that concentrates urine without raising blood pressure. It is approved for diabetes insipidus, bedwetting, nocturia and some bleeding disorders. A Cochrane review of 14 trials found it reduces night-time voids by a little under one per night in men. Its serious risk is hyponatraemia — low blood sodium — in about 7.6% of older adults, which is why sodium is monitored. It is on WADA's list as a masking agent.
Desmopressin is approved (rx). Legal status differs by country — see the regulation section or the jurisdiction pages.
Questions
Is Desmopressin proven to cause hyponatraemia?
What studies are behind the grade?
Is Desmopressin approved for this?
Other outcomes for Desmopressin
- ANocturia (night-time voids)Cochrane review, 14 RCTs (n=2,966 men)
- ACentral diabetes insipidusDecades of use; the original indication
- ANocturnal enuresis in childrenCochrane review (2025 update)
Written and maintained by LYO Research — how pages are written and checked. Reviewed 23 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →